Targeting tumor metabolism with 2-deoxyglucose in patients with castrate-resistant prostate cancer and advanced malignancies. - Wikidata - wikimedia - TriplyDB

Targeting tumor metabolism with 2-deoxyglucose in patients with castrate-resistant prostate cancer and advanced malignancies.

Targeting tumor metabolism with 2-deoxyglucose in patients with castrate-resistant prostate cancer and advanced malignancies.

http://www.wikidata.org/entity/Q34081705

about

Novel drugs that target the metabolic reprogramming in renal cell cancer New Potential Pharmacological Functions of Chinese Herbal Medicines via Regulation of Autophagy Energy disruptors: rising stars in anticancer therapy?Autophagy and cancer cell metabolism Warburg effect, hexokinase-II, and radioresistance of laryngeal carcinoma A phase I dose-escalation trial of 2-deoxy-D-glucose alone or combined with docetaxel in patients with advanced solid tumors Inhibition of 6-phosphofructo-2-kinase (PFKFB3) induces autophagy as a survival mechanism Hypoxia-inducing factors as master regulators of stemness properties and altered metabolism of cancer- and metastasis-initiating cells 2-Deoxy-D-glucose treatment induces ketogenesis, sustains mitochondrial function, and reduces pathology in female mouse model of Alzheimer's disease Medium Renewal Blocks Anti-Proliferative Effects of Metformin in Cultured MDA-MB-231 Breast Cancer Cells A metabolic perturbation by U0126 identifies a role for glutamine in resveratrol-induced cell death.Functional molecular imaging of tumors by chemical exchange saturation transfer MRI of 3-O-Methyl-D-glucose.Combined treatment with Metformin and 2-deoxy glucose induces detachment of viable MDA-MB-231 breast cancer cells in vitro.Antiangiogenic activity of 2-deoxy-D-glucose.A validated bioanalytical HPLC method for pharmacokinetic evaluation of 2-deoxyglucose in human plasma.Anticancer targets in the glycolytic metabolism of tumors: a comprehensive review Exploring a glycolytic inhibitor for the treatment of an FH-deficient type-2 papillary RCC Principles and current strategies for targeting autophagy for cancer treatment.Inhibition of KIT-glycosylation by 2-deoxyglucose abrogates KIT-signaling and combination with ABT-263 synergistically induces apoptosis in gastrointestinal stromal tumor.Autophagy in tumor suppression and cancer therapy.Frequent gene products and molecular pathways altered in prostate cancer- and metastasis-initiating cells and their progenies and novel promising multitargeted therapies.2-Deoxy-d-Glucose Can Complement Doxorubicin and Sorafenib to Suppress the Growth of Papillary Thyroid Carcinoma Cells.Chronic Dietary Administration of the Glycolytic Inhibitor 2-Deoxy-D-Glucose (2-DG) Inhibits the Growth of Implanted Ehrlich's Ascites Tumor in Mice Mitochondrial-Targeted Decyl-Triphenylphosphonium Enhances 2-Deoxy-D-Glucose Mediated Oxidative Stress and Clonogenic Killing of Multiple Myeloma Cells Activation of the unfolded protein response by 2-deoxy-D-glucose inhibits Kaposi's sarcoma-associated herpesvirus replication and gene expression.Unfolded protein response to autophagy as a promising druggable target for anticancer therapy.Anticancer agents that counteract tumor glycolysis.Combination of glycolysis inhibition with chemotherapy results in an antitumor immune response.MCT1-mediated transport of a toxic molecule is an effective strategy for targeting glycolytic tumors.Targeting glucose metabolism in cancer: new class of agents for loco-regional and systemic therapy of liver cancer and beyond?Clinical development of cancer therapeutics that target metabolism.2-Deoxy-d-Glucose Ameliorates PKD Progression.Emerging metabolic targets in the therapy of hematological malignancies.The role of autophagy in cancer: therapeutic implications.Mitochondrial metabolism inhibitors for cancer therapy.The wonders of 2-deoxy-D-glucose.2-Deoxy-Glucose Downregulates Endothelial AKT and ERK via Interference with N-Linked Glycosylation, Induction of Endoplasmic Reticulum Stress, and GSK3β Activation.Targeting of cell metabolism in human acute myeloid leukemia--more than targeting of isocitrate dehydrogenase mutations and PI3K/AKT/mTOR signaling?Resveratrol augments ER stress and the cytotoxic effects of glycolytic inhibition in neuroblastoma by downregulating Akt in a mechanism independent of SIRT1.BIRC5/Survivin as a target for glycolysis inhibition in high-stage neuroblastoma.

P2860

Q26740187-289AAE40-96ED-4A06-8D1C-AAE208931EEC Q26753053-45B466F0-A866-492E-9AF6-16BA044430B8 Q26771300-DC5F9DA2-51ED-49E2-9BBE-6963274B48E2 Q27022418-E9CB2BEA-990B-495E-A14B-21A377A515E7 Q28072714-608D9F6A-D594-4649-A3B1-A86375770158 Q28281237-15EB99B9-6AE3-4320-808D-3EBA57DF265E Q28306357-41A18322-BA5E-48AC-A625-EC1754DDE821 Q28393898-160F37FA-88A4-4A7D-90FF-B92B78EDDB8D Q28478912-E0430F7A-BC3B-4543-A735-F618ED783F68 Q28551723-D9B0D301-20A2-4D40-8EBE-2093B8D21356 Q30423585-7CD0FDB5-87F6-48AB-9123-4CA37B462EFF Q30853802-163A9E67-060B-4837-861E-F3A8FC597E79 Q33687560-AF8C4F74-529D-4A5C-BD6F-EC82A00AA6C6 Q33742196-63ACF4D2-4AA0-4E35-931A-E3070AA1AEDD Q34024304-FD6B90D6-5423-4A3E-9F68-CDC694BC27BF Q34028478-7171281A-3C39-41FA-9B60-6DD2D526A76B Q34663243-40B68E75-4743-4764-9B3D-B61D9F43F714 Q34787732-82B505E1-674C-4928-9799-BD5E1F0390AA Q35189301-928F8173-8354-4EBA-B655-D3256204DEA2 Q35276016-D7A8B728-D023-407C-9201-B7E9E3CE087F Q35287094-7941BC83-7BD5-4911-813A-5C29E273F31B Q35680684-5A0BBC36-C7F5-4E81-954D-204C176D1781 Q35681147-33775C18-9CF8-44EA-AEBB-213B89B354EB Q36208283-F2CD3DC0-C67D-4DEB-8041-4D8C63113B63 Q36364238-0BF7E3CB-31CD-471A-8732-3959D2950B98 Q36403652-87011278-2983-45A5-990A-7C262D90DF36 Q36452381-5935103E-AD56-42EB-AD20-D7D32542F45B Q36471376-3F8522F1-E4E8-4DE4-AB8D-B5B01D7085A9 Q36489907-DE4505FA-443B-487A-907A-B1C0AA239BED Q36687966-D9846C34-ADDF-4447-ACCD-BD39430FB051 Q36988292-FA3A3832-5B7F-4568-A880-CE44CEC54087 Q37051989-020E14D3-CA07-4B59-81F6-7A6F9627699A Q37137623-1F2AA231-9981-4603-9A41-832E13433C7C Q37924056-CE2477B2-69A1-4D3C-8B93-2E4D737BC529 Q37932441-19E77EE1-A461-4997-A907-F3F57A3DE26F Q38191881-9EF6464D-954F-46AE-B7CF-AD04114A255B Q38324927-71531694-E604-4CB4-98E9-9B212EE637A0 Q38606849-28F28BBC-8E70-43C1-AE22-332A013ED539 Q38792925-3BB868CB-A515-45D6-A5AA-D158596DCBDB Q38856274-E94C7C86-0C55-46BD-80CA-F32222EF8EBB

P2860

Targeting tumor metabolism with 2-deoxyglucose in patients with castrate-resistant prostate cancer and advanced malignancies.

http://www.wikidata.org/entity/Q34081705

description

2010 nî lūn-bûn

@nan

2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Targeting tumor metabolism wit ...... cer and advanced malignancies.

@ast

Targeting tumor metabolism wit ...... cer and advanced malignancies.

@en

Targeting tumor metabolism wit ...... cer and advanced malignancies.

@nl

type

label

Targeting tumor metabolism wit ...... cer and advanced malignancies.

@ast

Targeting tumor metabolism wit ...... cer and advanced malignancies.

@en

Targeting tumor metabolism wit ...... cer and advanced malignancies.

@nl

prefLabel

Targeting tumor metabolism wit ...... cer and advanced malignancies.

@ast

Targeting tumor metabolism wit ...... cer and advanced malignancies.

@en

Targeting tumor metabolism wit ...... cer and advanced malignancies.

@nl

P1433

Q34081705-D0CD88C6-1499-4E34-86B6-1CEB67CC8BAC

P1476

Q34081705-D2D456D6-7AB3-4D03-9BA9-363B396A7F6D

P2093

Q34081705-0E212DDD-2E8B-4812-B790-E9D19C588933

Q34081705-1AA3876E-F9BD-4ECB-B5FD-0B8CD3CA835A

Q34081705-3A0FAEF5-B2EA-40BD-AC0A-03E94AF479C2

Q34081705-589CBAA2-20E9-42C9-8286-39C3D95EF9DD

Q34081705-5A1CA637-68F7-4905-B03A-D86A62AB596D

Q34081705-5C101851-5C71-4948-A917-6DF82E286D4F

Q34081705-A81F6441-FABB-4BC8-8E70-8EF87F1D0DB2

Q34081705-C48DFE57-75A6-4C45-AA0B-8B755D4A4CE2

Q34081705-F6FE3F3C-D9E7-4743-BB2E-6D46C02F6ADA

P2860

Q34081705-0324BF99-8E20-4C64-90BE-9B41F750E9AF

Q34081705-1B561758-FA6F-47F0-A58F-8F840686C07A

Q34081705-1F36D2EE-0F5B-43A7-9834-0C050EB2922F

Q34081705-2EA0DF14-913E-40B0-8AA0-B9C87D4FA773

Q34081705-344DAF2F-3188-4615-9340-71CFEAA4CE65

Q34081705-3CCBDC38-4F0F-4C2B-B71F-6EA04C904CD8

Q34081705-41EDB698-A875-4513-8CB1-82DC147231A8

Q34081705-58B92151-6BC7-405B-907D-EF5B0DD37CF0

Q34081705-649EBD4B-3079-47C4-A979-737ACD97B072

Q34081705-75992359-54D1-4828-8DE4-5360A1297CCD

P304

Q34081705-F5F0647F-F1C6-4195-A14C-0F865447DEE6

P31

Q34081705-82DD216E-6DB8-47DF-BC49-87CDF8100CBB

P356

Q34081705-DD5659F0-C359-4072-94D5-727E3A1D260B

P433

Q34081705-A1B44267-4E76-4963-80B8-9A249EA3FB1C

P478

Q34081705-39AE652E-4A08-4A62-BEE8-34A027545CAE

P50

Q34081705-FA9EA17D-41D3-473E-9A59-6264D804BCB6

P577

Q34081705-8E817DF5-BF31-44FA-A4F6-85A0CFC652A5

P698

Q34081705-93122D66-0F16-4396-A9D0-93835A55720F

P921

Q34081705-2F231FA9-66C0-45D4-920A-7086E47AA565

P932

Q34081705-D04C8491-F66E-4C33-A7B5-37E5FA4D63B0

P356

P1433

P1476

Targeting tumor metabolism wit ...... cer and advanced malignancies.

@en

P2093

Chandrika Jeyamohan

http://www.w3.org/2001/XMLSchema#string

Dmitri Dvorzhinski

http://www.w3.org/2001/XMLSchema#string

Hongxia Lin

http://www.w3.org/2001/XMLSchema#string

Kevin Bray

http://www.w3.org/2001/XMLSchema#string

Mark Stein

http://www.w3.org/2001/XMLSchema#string

Murugesan Gounder

http://www.w3.org/2001/XMLSchema#string

Robert S Dipaola

http://www.w3.org/2001/XMLSchema#string

Simantini Eddy

http://www.w3.org/2001/XMLSchema#string

Susan Goodin

http://www.w3.org/2001/XMLSchema#string

P2860

Understanding the Warburg effect: the metabolic requirements of cell proliferation

Autophagy suppresses tumorigenesis through elimination of p62

AKT/PKB signaling: navigating downstream

Localization of the primary metabolic block produced by 2-deoxyglucose

Glycolysis inhibition for anticancer treatment

An expanding role for mTOR in cancer

Akt stimulates aerobic glycolysis in cancer cells

mTOR-targeted therapy of cancer with rapamycin derivatives.

Structure, regulation and function of PKB/AKT--a major therapeutic target.

PI 3-kinase, Akt and cell survival.

P304

1388-1394

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/PROS.21172

http://www.w3.org/2001/XMLSchema#string

P433

13

http://www.w3.org/2001/XMLSchema#string

P478

70

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20687211

http://www.w3.org/2001/XMLSchema#string

P921

P932

4142700

http://www.w3.org/2001/XMLSchema#string